Yasuoka Hidekata, Larregina Adriana T, Yamaguchi Yukie, Feghali-Bostwick Carol A
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Open Rheumatol J. 2008;2:17-22. doi: 10.2174/1874312900802010017. Epub 2008 Mar 28.
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. A hallmark of SSc is fibrosis of the skin and internal organs. We recently demonstrated increased expression of IGFBP-3 and IGFBP-5 in primary cultures of fibroblasts from the skin of patients with SSc. In vitro, IGFBP-3 and IGFBP-5 induced a fibrotic phenotype and IGFBP-5 triggered dermal fibrosis in mice. To assess the ability of IGFBPs to trigger fibrosis, we used an ex vivo human skin organ culture model. Our findings demonstrate that IGFBP-3 and IGFBP-5, but not IGFBP-4, increase dermal and collagen bundle thickness in human skin explants, resulting in substantial dermal fibrosis and thickening. These fibrotic effects were sustained for at least two weeks. Our findings demonstrate that human skin ex vivo is an appropriate model to assess the effects of fibrosis-inducing factors such as IGFBPs, and for evaluating the efficacy of inhibitors/therapies to halt the progression of fibrosis and potentially reverse it.
系统性硬化症(SSc)是一种病因不明的结缔组织疾病。SSc的一个标志是皮肤和内脏器官的纤维化。我们最近证明,在系统性硬化症患者皮肤成纤维细胞的原代培养物中,IGFBP - 3和IGFBP - 5的表达增加。在体外,IGFBP - 3和IGFBP - 5诱导纤维化表型,IGFBP - 5引发小鼠皮肤纤维化。为了评估IGFBPs引发纤维化的能力,我们使用了一种体外人皮肤器官培养模型。我们的研究结果表明,IGFBP - 3和IGFBP - 5而非IGFBP - 4会增加人皮肤外植体的真皮和胶原束厚度,导致明显的真皮纤维化和增厚。这些纤维化效应持续了至少两周。我们的研究结果表明,体外人皮肤是评估诸如IGFBPs等纤维化诱导因子的作用以及评估抑制剂/疗法阻止纤维化进展并可能逆转纤维化疗效的合适模型。